{"filing":{"accession_number":"0001140361-26-025324","cik":"0001124105","ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","form":"8-K","filing_date":"2026-06-16","report_date":null,"primary_document":"ef20076059_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126025324/ef20076059_8k.htm"},"events":[{"id":11185,"run_id":9805,"accession_number":"0001140361-26-025324","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This Item 5.07 disclosure reports the final voting results from Gyre Therapeutics' June 10, 2026 Annual Meeting of Stockholders, including election of directors (David M. Epstein and Dan Weng), non-binding advisory vote on executive compensation, ratification of Grant Thornton Zhitong as independent auditor, and approval of Series B Preferred Stock conversion. The filing presents tabulated vote counts for each proposal, which is the core content of a shareholder_vote_results event.","company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","filing_date":"2026-06-16","form":"8-K","submitted_at":null,"items":[{"id":7717,"accession_number":"0001140361-26-025324","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure reports the final voting results from Gyre Therapeutics' June 10, 2026 Annual Meeting of Stockholders, including election of directors (David M. Epstein and Dan Weng), non-binding advisory vote on executive compensation, ratification of Grant Thornton Zhitong as independent auditor, and approval of Series B Preferred Stock conversion. The filing presents tabulated vote counts for each proposal, which is the core content of a shareholder_vote_results event.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-16T10:33:05.925177+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7717,"accession_number":"0001140361-26-025324","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure reports the final voting results from Gyre Therapeutics' June 10, 2026 Annual Meeting of Stockholders, including election of directors (David M. Epstein and Dan Weng), non-binding advisory vote on executive compensation, ratification of Grant Thornton Zhitong as independent auditor, and approval of Series B Preferred Stock conversion. The filing presents tabulated vote counts for each proposal, which is the core content of a shareholder_vote_results event.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-16T10:33:05.925177+00:00","company_name":"GYRE THERAPEUTICS, INC.","ticker":"GYRE","filing_date":"2026-06-16"}]}